Inflammation in Heart Failure

Highlights

• Inflammation contributes to the pathogenesis of HF and may be a biotarget for therapy.

• Although clinical trials of anti-inflammatory therapies have failed, targeting inflammation in specific sub-phenotypes may yet prove successful.

• Potential anti-inflammatory targets include inhibition of IL-1β, IL-6, and galectin-3.

Abstract

It has long been observed that heart failure (HF) is associated with measures of systemic inflammation. In recent years, there have been significant advancements in our understanding of how inflammation contributes to the pathogenesis and progression of HF. However, although numerous studies have validated the association between measures of inflammation and HF severity and prognosis, clinical trials of anti-inflammatory therapies have proven mostly unsuccessful. On this backdrop emerges the yet unmet goal of targeting precise phenotypes within the syndrome of HF; if such precise definitions can be realized, and with better understanding of the roles played by specific inflammatory mediators, the expectation is that targeted anti-inflammatory therapies may improve prognosis in patients whose HF is driven by inflammatory pathobiology. Here, the authors describe mechanistic links between inflammation and HF, discuss traditional and novel inflammatory biomarkers, and summarize the latest evidence from clinical trials of anti-inflammatory therapies.